相关临床试验
291
184 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
136
46.7%
已完成
28
9.6%
尚未招募
48
16.5%
招募中
68
23.4%
暂停
2
0.7%
Unknown
6
2.1%
撤回
3
1.0%
暂无批准数据
- Illumina has launched TruPath Genome, a whole-genome sequencing workflow that eliminates traditional library prep and delivers 16 genomes per day in about 10 minutes of hands-on time. - The platform fully phases up to 98% of genes and extends accurate variant calling into difficult-to-map 'dark regions' of the genome using on-flow-cell library preparation and DRAGEN algorithms. - Data presented at AGBT showed TruPath Genome resolving challenging loci including the SMN1/SMN2 region in spinal muscular atrophy and genes linked to inherited adrenal disorders. - Broad Clinical Labs is among the first adopters, while more than 30 early access customers including GeneDx, Rady Children's Hospital and Baylor College of Medicine piloted the technology over 16 months.
- An international team identified a mutation in the OTULIN gene as the cause of pediatric-onset pyoderma gangrenosum, classifying it as a new inborn error of immunity. - The mutation uncouples OTULIN's enzymatic activity from its interaction with a ubiquitination complex, leading to elevated TNF and IL-1β levels and heightened sensitivity to TNF-dependent cell death. - One patient with treatment-resistant skin sores achieved successful clinical response with TNF blockade therapy. - The findings, published in Nature Immunology, highlight the role of linear ubiquitin signaling in human health and open avenues for targeted therapeutic intervention.
- The RepurpSS-II phase 2b trial demonstrated that leflunomide combined with hydroxychloroquine significantly reduced systemic disease activity in patients with moderate-to-severe Sjögren's disease compared to placebo. - At 24 weeks, the ESSDAI score was 4.135 points lower in the treatment arm, replicating the earlier phase 2a RepurpSS-I results and validating the combination's efficacy. - Both drugs are existing, inexpensive oral tablets, making this a potentially accessible treatment option worldwide, including in low-income countries. - No clinically significant safety concerns were observed, with gastrointestinal events being the most common adverse effect.
- The Philips-coordinated PreciseOnco consortium has been awarded €14.9 million in EU funding to develop integrated spectral imaging, robotic guidance, and AI technologies for minimally invasive cancer treatment. - The five-year research program will conduct five clinical studies across multiple cancer types to validate spectral imaging and robotic guidance systems with sub-millimeter precision. - The initiative addresses the growing cancer burden, with projections of over 35 million new cases globally by 2050, representing a 77% increase from 2022. - The consortium unites leading European hospitals, research organizations, and industry partners to standardize and enhance precision in interventional oncology procedures.
- Dupilumab showed the highest 2-year drug survival rates among targeted atopic dermatitis therapies, with 77.3% survival in treatment-naïve patients and 68.1% in previously treated patients. - JAK inhibitors demonstrated lower persistence rates, with drug discontinuation primarily due to insufficient effectiveness (20.6%) and adverse events (13.7%). - The introduction of new targeted therapies doubled the risk of dupilumab discontinuation, indicating that treatment availability significantly influences drug survival outcomes. - Tralokinumab provided clinical benefit for 51% of patients who failed dupilumab therapy, offering a viable alternative for biologic sequencing strategies.
- The COVID-RED trial, involving 17,825 participants, demonstrated that a wearable device algorithm combined with symptom reporting detected SARS-CoV-2 infections significantly earlier than symptom-only screening (median 0 vs 7 days before positive test). - The experimental algorithm achieved very high sensitivity (93.8-99.2%) but extremely low specificity (0.8-4.2%), generating many false positive alerts compared to the control algorithm's moderate performance (43.3-46.4% sensitivity, 66.4-65.0% specificity). - Researchers plan to refine the algorithm using improved machine learning methodologies and better alert thresholds to reduce false positives while maintaining early detection capabilities for COVID-19 and potentially other respiratory infections.
- Preliminary results from the ERECT trial demonstrate that Elekta Unity MR-Linac significantly reduces erectile dysfunction rates in prostate cancer patients compared to conventional radiotherapy. - The MR-guided radiotherapy system enables precise visualization of critical structures, allowing physicians to deliver therapeutic doses to the prostate while minimizing radiation exposure to erectile tissues. - At 18 months post-treatment, only 16% of patients treated with neurovascular-sparing MR-guided radiotherapy experienced erectile dysfunction, compared to 36% in the control group.
